天津医药

• 论著 •    

雷洛昔芬对绝经期后乳腺癌VEGF、Ki-67、CD34抗原表达的影响

侍晓辰,张卫东,周仕萍   

  1. 无锡市中医医院
  • 收稿日期:2011-06-10 修回日期:2011-09-14 出版日期:2012-03-15 发布日期:2012-03-15
  • 通讯作者: 侍晓辰

Influence of raloxifene on VEGF、Ki-67、CD34 antigen expression in postmenopausal women with breast carcinoma

  • Received:2011-06-10 Revised:2011-09-14 Published:2012-03-15 Online:2012-03-15
  • Contact: Xiao-Chen SHI

PDF (PC)

2098

摘要： 目的：探讨雷洛昔芬对绝经期后乳腺癌血管内皮生长因子（vascuoar endothelial cell growth factor，VEGF）、Ki-67、CD34抗原表达的影响及其意义。方法：20例绝经期后乳腺浸润性导管癌（TMN分期Ⅱ期，雌激素受体阳性）妇女口服雷洛昔芬60 mg/d，连续用药21 d，采用免疫组化法检测治疗前后肿瘤组织VEGF、Ki-67、CD34抗原表达情况，对所得结果进行比较分析。结果：雷洛昔芬治疗前后VEGF表达阳性率分为85% （17/20）和30% （6/20），差异有统计学意义(χ2=12.38, P<0.01)。雷洛昔芬治疗前后Ki-67阳性细胞百分数分别为（19.36±1.66）%和（12.24±1.42）%，差异有统计学意义（t=2.86, P<0.01）。雷洛昔芬治疗前后CD-34抗原标记的肿瘤微血管数量分别为46.25±3.88和23.64±1.53，差异有统计学意义（t=2.93, P<0.01）。结论：雷洛昔芬可抑制绝经期后妇女乳腺癌肿瘤细胞的增殖活性及肿瘤组织的微血管形成，这一作用可能是通过抑制肿瘤VEGF的表达实现。

关键词: 乳腺癌, 雷洛昔芬, VEGF, Ki-67, CD34, 免疫组化

Abstract: Objective: To exploring the influence of raloxifene on vascular endothelial growth factor (VEGF), Ki-67, CD34 antigen expression in postmenopausal women with breast carcinoma. Methods: Twenty postmenopausal patients with TMN stage II, estrogen receptor(+) breast cancer was involved in this research, and all of them took raloxifene 60mg/d for 21 days. Immunohistochemistry was carried out in tumor samples to evaluate VEGF, Ki-67, CD34 antigen expression prior to and following raloxifene treatment, respectively. Result: VEGF-positive expression rate was 85% prior to raloxifene treatment, while only 30% (χ2=12.38, P<0.01) following treatment; and the mean percentage of Ki-67-positive nuclei was (19.36±1.66)% and (12.24±1.42)% (t=2.86, P<0.01) prior to and following raloxifene treatment, respectively. The mean number of microvessels was 46.25±3.88 prior to raloxifene therapy and 23.64±1.53 (t=2.93, P<0.01) following therapy. Conclusion: Raloxifene has an effect of depressing cell proliferation activity and formation of new blood vessels in breast carcinoma tissue of postmenopausal women, and the effect might be achieve through depressing VEGF expression of tumor tissue.

Key words: breast carcinoma, raloxifene, VEGF, Ki-67, CD34, Immunohistochemistry